Table 3 Congruency of treatment recommendations for skin infections in adults with national commensal S. aureus resistance rates
Topical AB | Resistance rate* | First choice systemic AB | Resistance rate* | Second choice systemic AB | Resistance rate* | |
|---|---|---|---|---|---|---|
Impetigo | ||||||
Austria | Fusidic acid | 1.0 | Cephalosporin | No data | Amoxicillin + Clavulanic acid | 1.5 |
Belgium | Fusidic acid | 3.4 | Flucloxacillin | 2.2 | Clarithromycin | 16.3 |
France | Fusidic acid | 4.0 | No specific advice | |||
Hungary | No guideline | |||||
Netherlands | Fusidic acid | 5.2 | Flucloxacillin | 1.0 | Azithromycin | 6.9 |
Spain | Mupirocin | 1.6 | Penicillin (IM)/Cloxacillin | 86.0 | Clindamycin | 9.5 |
1.3 | ||||||
Sweden | Retapamulin | 0 | Flucloxacillin | 0 | Cefadroxil | No data |
UK | Fusidic acid | 7.8 | Flucloxacillin | 1.6 | Clarithromycin | 8.9 |
Cellulitis | ||||||
Austria | Penicillin (parenteral) | 64.4 | Clindamycin | 11.1 | ||
Belgium | Flucloxacillin | 2.2 | Clindamycin | 14.4 | ||
France | No guideline | |||||
Hungary | No guideline | |||||
Netherlands | Flucloxacillin | 1.0 | Claritromycin | 5.5 | ||
Spain | Cloxacillin | 1.3 | Amoxicillin + Clavulanic acid | 1.3 | ||
Sweden | No guideline | |||||
UK | Flucloxacillin | 1.6 | Ery/Clarithromycin | 8.9 | ||
Folliculitis and Furuncle | ||||||
Austria | Cephalosporin | No data | Amoxicillin + Clavulanic acid | 1.5 | ||
Belgium | No guideline | |||||
France | No guideline | |||||
Hungary | No guideline | |||||
Netherlands | Flucloxacillin | 1.0 | No second choice | |||
Spain | Cloxacillin | 1.3 | No second choice | |||
Sweden | Flucloxacillin | 0 | Cefadroxil | No data | ||
UK | Flucloxacillin | 1.6 | Ery/Clarithromycin | 8.9 | ||